Hydroxychloroquine shows potential to treat COVID-19, a preprint claims

Preprints are yet to be peer-reviewed and published in a medical journal.

April 02, 2020 12:08 pm | Updated 12:10 pm IST - CHENNAI:

File photo of Nivaquine, tablets containing chloroquine, a commonly used malaria drug that has shown signs of effectiveness against COVID-19.

File photo of Nivaquine, tablets containing chloroquine, a commonly used malaria drug that has shown signs of effectiveness against COVID-19.

A small trial involving 62 COVID-19 patients admitted to the Renmin Hospital of Wuhan University has found that the malaria drug hydroxychloroquine given to patients helps shorten the time to clinical recovery. The trial had a treatment and a control arm of 31 patients each.

The results of the trial were posted on preprint server medRxiv on March 31. Preprints are yet to be peer-reviewed and published in a medical journal.


Also read: Health Ministry allows Hydroxychloroquine with Azithromycin for COVID-19


The researchers from the Renmin Hospital of Wuhan University found that nearly 81% (25 of 31) of patients in the treatment group showed improved pneumonia compared with the control group (55% or 17 of 31 patients). Only four of 62 patients progressed to severe illness and all the four were in the control arm. Two patients had mild adverse reaction (rash and headache) to the drug, while no severe side effects were seen.

Approval by ICMR

Based on the recommendation of the Task Force for coronavirus disease (COVID-19), on March 23, the Indian Council of Medical Research (ICMR) approved the use of hydroxychloroquine as prophylaxis by healthcare workers taking care of suspected or confirmed COVID-19 cases and asymptomatic household contacts of confirmed cases.


Also read: Opinion | Researchers in India must join the fight against COVID-19


India is all set to join World Health Organisation’s multi-country “solidarity trial” aimed at testing four drug combinations, including chloroquine, to treat COVID-19. On March 29, the Food and Drug Administration issued an emergency use authorisation for hydroxychloroquine and chloroquine for COVID-19 treatment.

Deaths reported

Soon after U.S. President Donald Trump championed for hydroxychloroquine as a treatment for COVID-19, two Nigerians are reported to have over-dosed on the drug. A man in Arizona, U.S., died and his wife was hospitalised after they self-medicated with a home remedy of hydroxychloroquine. A doctor in India died after taking two doses of the drug.

Outcome of the trial

Patients in the treatment arm received hydroxychloroquine 400 mg per day in addition to standard treatment for five consecutive days, while those in the control group received only the standard treatment. Patients were randomly assigned to either the treatment or control group.

The researchers looked for changes in the time taken for clinical recovery, which was defined as return to normal body temperature and cough relief for more than three days. They also looked for radiological changes using chest CT.

While 22 of 31 patients in the treatment group and 17 of 31 patients in the control group had a fever when the trial began, the time taken to achieve normal body temperature was “significantly shorter” for the treatment group, the preprint says. Also, cough remission was “significantly reduced” in the treatment group.


Also read: Coronavirus | Can drugs for Ebola be used to treat COVID-19?


Chest CT showed pneumonia condition improved in 25 of 31 patients (nearly 81%) in the treatment group compared with 17 of 31 (55%) patients in the control group. Of the 81% who showed improved pneumonia in the treatment group, 61% had “significant pneumonia absorption”.

“Despite our small number of cases, the potential of HCQ in the treatment of COVID-19 has been partially confirmed,” they write.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.